IARTIntegra LifeSciences Holdings Corporation
$11.91-19% 1Y
$11.91
$8.9052 weeks$19.87
IART in its own filings
IART's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
620
Events found in the filings · across 2,114 filings · the record starts in 1996
- Hard flags
- 2
Hard flags
- Most recent filing
- Oct 21, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 14, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Jan 20, 2027
- Late periodic report5 occurrences
- 2009-03-03
- Delisting notice / listing-rule failure2 occurrences
- 2008-05-23
- Material impairmenthistorical
- 2023-05-23
- SEC comment-letter activity15 occurrences
- 2012-12-11
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 21, 2026Integra LifeSciences Reports Third Quarter 2026 Financial Results.Earnings release · press release
- Oct 19, 2026On October 19, 2026, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amended and restated credit agreement with a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and a L/C Issuer (the “Credit Agreement”)Material agreement entered · Form 8-K
- Oct 9, 2026Integra Announces Pricing of Senior Secured Notes.Regulation FD disclosure · press release
- Oct 2, 2026Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance.Earnings release · press release
- Jul 29, 2026Integra LifeSciences Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 8, 2026Integra LifeSciences Holdings Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 7, 2026.Director or officer change · Form 8-K
- May 5, 2026Appointment of Dr. Stuart Essig as President and Chief Executive Officer On May 5, 2026, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the “Start Date”)Director or officer change · Form 8-K
- May 5, 2026Integra LifeSciences Reports First Quarter 2026 Financial Results.Earnings release · press release
- Apr 15, 2026As previously disclosed, on December 18, 2018, certain subsidiaries of Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), entered into a $150 million accounts receivable securitization facility (the “A/R Facility”) to reduce outstanding revolving borrowings under the Company’s senior …Material agreement entered · Form 8-K
- Feb 26, 2026Integra LifeSciences Reports Fourth Quarter and Full-Year 2025.Earnings release · press release
- Dec 12, 2025On December 11, 2025, Integra LifeSciences Holdings Corporation (the “Company”) adopted a change in control severance program (the “Program”) under which certain executives of the Company, including Lea Knight, Executive Vice President and Chief Financial Officer, Robert T. Davis, Jr., Executive Vice President …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Devices
Ranks #14 of 50 by RyuScore